The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
9 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $2,952,040 in first-year total cost, median $269,263.
Most frequent study sections
- Special Emphasis Panel[ZRG1 MCST-M (81)]7
- Advancing Therapeutics - B Study Section[ATB]2
Most frequent institutions
- CHILDREN'S MERCY HOSP (KANSAS CITY, MO)1
- ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI1
- NEUROSANT THERAPEUTICS LLC1
- PENNSYLVANIA STATE UNIVERSITY, THE1
- STATE UNIVERSITY OF NY,BINGHAMTON1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Verification of pigs as an appropriate model for the development of human vaccines targeting the entero-mammary pathway to elicit a robust secretory IgA response in human milk1R21AI182913-01A1 | POWELL, REBECCA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $477,406 | ZRG1 |
| 2025 | A Novel Physiologically Based Pharmacokinetic (PBPK) Modeling Approach to Facilitate Safer Medications During Lactation1R21HD115866-01A1 | ZHANG, TAO | STATE UNIVERSITY OF NY,BINGHAMTON, NY | $448,182 | ATB |
| 2025 | Milk Protein-Based Amorphous Solid Dispersion for Delivery of Hydrophobic APIs1R21HD117135-01 | HARTE, FEDERICO M | PENNSYLVANIA STATE UNIVERSITY, THE, PA | $428,208 | ZRG1 |
| 2025 | Optimizing Betamethasone Therapy for Preventing Respiratory Distress Syndrome in Twin Pregnancy1R21HD119501-01 | DE MORAES, NATALIA VALADARES | UNIVERSITY OF FLORIDA, FL | $419,375 | ATB |
| 2024 | CMV+ milk: morbidity risk & translational potential of neutralizing antibodies1R21HD115905-01 | MARTIN, CAMILIA R | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $269,263 | ZRG1 |
| 2024 | Inhaled ciclesonide - a phase I study in preterm infants1R21HD116421-01 | SAMPATH, VENKATESH | CHILDREN'S MERCY HOSP (KANSAS CITY, MO), MO | $250,300 | ZRG1 |
| 2024 | Structure-based antisense therapeutics targeting dystrophin exons 44 and 45 for Duchenne Muscular Dystrophy1R21HD115071-01 | GUO, FENGMICELI, M CARRIE | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $236,250 | ZRG1 |
| 2024 | Maternal-infant transfer of microbial modified immunity1R21AI182934-01 | LIU, YUYING | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, TX | $234,000 | ZRG1 |
| 2024 | Therapeutics that Correct the Underlying Cause of Smith-Magenis Syndrome (SMS)1R21HD115076-01 | DEFREES, SHAWNHUANG, WEI-HSIANG | NEUROSANT THERAPEUTICS LLC, CA | $189,056 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.